YH 22162

Drug Profile

YH 22162

Alternative Names: Amlodipine/chlortalidone/telmisartan - Yuhan; YH22162 FDC

Latest Information Update: 24 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yuhan
  • Class Antihypertensives; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Essential hypertension

Most Recent Events

  • 01 Dec 2016 Yuhan Corporation completes a phase III trial in Essential hypertension (Treatment-experienced) in South Korea (PO) (NCT02620163)
  • 01 Dec 2015 Phase-III clinical trials in Essential hypertension (Treatment-experienced) in South Korea (PO) (NCT02620163)
  • 01 Jun 2015 Yuhan initiates enrolment in a phase I bioequivalence trial in Essential hypertension (In volunteers) in South Korea (PO) (NCT02496910)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top